Dachaigh › Carcinoma Neuroendocrine
Sgrùdaidhean clionaigeach Carcinoma Neuroendocrine a’ fastadh anns na SA
Tha 16 sgrùdaidhean airson Carcinoma Neuroendocrine a’ fastadh phàirtichean aig làraichean air feadh nan Stàitean Aonaichte.
Bailtean leis na sgrùdaidhean as motha
- Houston, TX6 sgrùdaidhean
- New York City, NY6 sgrùdaidhean
- Arlington, VA5 sgrùdaidhean
- Dallas, TX4 sgrùdaidhean
- Los Angeles, CA4 sgrùdaidhean
- Washington, DC4 sgrùdaidhean
- St. Louis, MO3 sgrùdaidhean
- Columbus, OH3 sgrùdaidhean
- Grand Rapids, MI3 sgrùdaidhean
- New Haven, CT3 sgrùdaidhean
- Atlanta, GA3 sgrùdaidhean
- Denver, CO3 sgrùdaidhean
- Nashville, TN3 sgrùdaidhean
- Seattle, WA3 sgrùdaidhean
Le stàit
- California6 sgrùdaidhean
- Colorado4 sgrùdaidhean
- Connecticut3 sgrùdaidhean
- Florida5 sgrùdaidhean
- Georgia4 sgrùdaidhean
- Louisiana3 sgrùdaidhean
- Maryland6 sgrùdaidhean
- Michigan3 sgrùdaidhean
- Missouri3 sgrùdaidhean
- New Jersey4 sgrùdaidhean
- New York6 sgrùdaidhean
- Ohio4 sgrùdaidhean
- Tennessee4 sgrùdaidhean
- Texas8 sgrùdaidhean
- Virginia5 sgrùdaidhean
- Washington4 sgrùdaidhean
Sgrùdaidhean air an ùrachadh o chionn ghoirid
Teacsa sgrùdaidh oifigeil (Beurla)
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
A’ fastadhÌre 2
Aoisean 18 gu 120 · Gach gnè · Air ùrachadh 5 Dàmh 2026 · NCT06406465Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease
A’ fastadhÌre 1
Aoisean 18 gu 120 · Gach gnè · Air ùrachadh 5 Dàmh 2026 · NCT07509034A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors
A’ fastadhÌre 1
Aoisean 18 gu 120 · Gach gnè · Air ùrachadh 5 Dàmh 2026 · NCT06041516Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)
A’ fastadhSgrùdadh amharc
Aoisean 18 gu 120 · Gach gnè · Air ùrachadh 24 Sult 2026 · NCT05237934Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 22 Sult 2026 · NCT07278479Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 16 Sult 2026 · NCT07080242A Study of Armored CAR T Cells in People With Cancer
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 2 Sult 2026 · NCT07783477A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Lùna 2026 · NCT07488923A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 5 Lùna 2026 · NCT06330064A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 31 Iuch 2026 · NCT07129252A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 15 Iuch 2026 · NCT05652686Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
A’ fastadhÌre 1/2
Aoisean 18 gu 99 · Gach gnè · Air ùrachadh 13 Iuch 2026 · NCT05000294A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 9 Iuch 2026 · NCT07174583A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
A’ fastadhÌre 1/2
Aoisean 12 agus nas sine · Gach gnè · Air ùrachadh 27 Cèit 2026 · NCT03093116SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 28 Gibl 2026 · NCT06889493A Study of MT-4561 in Patients With Various Advanced Solid Tumors
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 11 Dùbh 2025 · NCT06943521Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.